|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
|
26678033 |
2016 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.
|
25370471 |
2015 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
|
24583796 |
2014 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Prognostic value of BRAF mutations in localized cutaneous melanoma.
|
24388723 |
2014 |
|
rs113488022
|
|
melanoma
|
G |
0.800 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
|
24576830 |
2014 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
|
24586605 |
2014 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
22972589 |
2013 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
|
23918947 |
2013 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAF(V600E) mutation-positive melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m(2) intravenously every 3 weeks).
|
22735384 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.
|
23031422 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
|
22356324 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
|
22351686 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF(V600E)- or MEK-inhibitors on melanoma cell viability in vitro and growth in athymic nude Foxn1 ( nu ) mice (P = .03 when mean tumor volume at day 13 was compared for BRAF(V600E) inhibitor vs BRAF(V600E) inhibitor plus CDK2/4 inhibition; P = .02 when mean tumor volume was compared for MEK inhibitor vs MEK inhibitor plus CDK2/4 inhibition; P values were calculated by a two-sided Welch t test; n = 4-8 mice per group).
|
22997239 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
|
22048237 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
|
22536370 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Improved survival with MEK inhibition in BRAF-mutated melanoma.
|
22663011 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
22805292 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
To identify determinants of acquired resistance to GSK2118436 and strategies to overcome the resistance, we isolated GSK2118436 drug-resistant clones from the A375 BRAF(V600E) and the YUSIT1 BRAF(V600K) melanoma cell lines.
|
22389471 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Efficacy at the recommended phase 2 dose was studied in patients with BRAF-mutant tumours, including those with non-Val600Glu mutations, in three cohorts: metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumours.
|
22608338 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
23020132 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |